- Home
- LANV vs IPHA Comparison
LANV vs IPHA Comparison
Compare LANV & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- IPHA
- Stock Information
- Founded
- LANV 2015
- IPHA 1999
- Country
- LANV China
- IPHA France
- Employees
- LANV N/A
- IPHA N/A
- Industry
- LANV Blank Checks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- LANV Finance
- IPHA Health Care
- Exchange
- LANV Nasdaq
- IPHA Nasdaq
- Market Cap
- LANV 219.4M
- IPHA 148.3M
- IPO Year
- LANV N/A
- IPHA 2019
- Fundamental
- Price
- LANV $1.85
- IPHA $1.79
- Analyst Decision
- LANV
- IPHA Strong Buy
- Analyst Count
- LANV 0
- IPHA 1
- Target Price
- LANV N/A
- IPHA $11.50
- AVG Volume (30 Days)
- LANV 92.6K
- IPHA 779.8K
- Earning Date
- LANV 02-19-2025
- IPHA 09-12-2024
- Dividend Yield
- LANV N/A
- IPHA N/A
- EPS Growth
- LANV N/A
- IPHA N/A
- EPS
- LANV N/A
- IPHA N/A
- Revenue
- LANV $409,961,427.00
- IPHA $36,202,722.00
- Revenue This Year
- LANV N/A
- IPHA N/A
- Revenue Next Year
- LANV $10.45
- IPHA $101.65
- P/E Ratio
- LANV N/A
- IPHA N/A
- Revenue Growth
- LANV N/A
- IPHA N/A
- 52 Week Low
- LANV $0.91
- IPHA $1.29
- 52 Week High
- LANV $3.78
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- LANV 46.31
- IPHA 45.92
- Support Level
- LANV $1.69
- IPHA $1.64
- Resistance Level
- LANV $2.09
- IPHA $1.87
- Average True Range (ATR)
- LANV 0.24
- IPHA 0.12
- MACD
- LANV -0.04
- IPHA -0.04
- Stochastic Oscillator
- LANV 25.97
- IPHA 28.66
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.